Download PDF
Aktuelle Dermatologie 2014; 40(01/02): 38-40
DOI: 10.1055/s-0033-1344984
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Dermatologische Therapie mit topischen Glukokortikoiden: aktueller Stand und zukünftige therapeutische Entwicklungen

Dermatological Treatment with Topical Corticosteroids: Current Status and Future Therapeutical Developments
D. Abeck
Gemeinschaftspraxis für Dermatologie und Allergologie, München
› Author Affiliations
Further Information

Publication History

Publication Date:
23 October 2013 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Topische Steroide bilden den Therapiestandard für eine Vielzahl entzündlicher Hauterkrankungen. Auch die längerfristige Anwendung ist bei Verwendung moderner Steroide mit hohem therapeutischen Index möglich. Die galenische Vielfalt erlaubt eine Stadien-adaptierte Behandlung. Neue Formulierungen bereits bekannter Kortikoide erweitern das Spektrum der Therapiemöglichkeiten.

Abstract

Topical corticosteroids are the standard-of-care treatment for a number of inflammatory skin diseases. Even their prolonged use is possible when steroids with a favourable benefit/risk ratio are applied. The galenic diversity allows a therapy related to the clinical picture. New formulations using known steroids will broaden the spectrum of therapeutic options.

 

  • Literatur

  • 1 Niedner R. Kortikoide in der Dermatologie. Bremen: Uni-Med; 1998
    Google Scholar
  • 2 Luger T, Loske KD, Elsner P et al. Topical skin therapy with glucocorticoids – the therapeutic index. J Dtsch Dermatol Ges 2004; 2629-2634
    PubMedGoogle Scholar
  • 3 Ashcrof DM, Dimmock P, Garside R et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005; 330: 516
    CrossrefPubMedGoogle Scholar
  • 4 Svensson A, Chambers C, Gånemo A et al. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Cur Med Res Opin 2011; 27: 1395-1406
    CrossrefPubMedGoogle Scholar
  • 5 Korting HC, Schöllmann C, Willers C et al. Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1 %. Skin Pharmacol Physiol 2012; 25: 133-141
    CrossrefPubMedGoogle Scholar
  • 6 Ruzicka T, Willers C, Wigger-Alberti W. Efficacy and patient-reported outcomes of a new mometasone cream treating atopic dermatitis. Skin Pharmacol Physiol 2012; 25: 305-312
    CrossrefPubMedGoogle Scholar
  • 7 Reygagne P, Mrowietz U, Decroix J et al. Clobetasol propionate shampoo 0.05 % and calcipotriol solution 0.005 %: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treatm 2005; 16: 31-36
    PubMedGoogle Scholar
  • 8 Zhao Y, Jones SA, Brown MB. Dynamic foams in topical drug delivery. J Pharm Pharmacol 2010; 62: 678-684
    PubMedGoogle Scholar
  • 9 Menter MA, Caveney SW, Gottschalk RW. Impact of clobetasol propionate 0.05 % spray on health-related quality of life in patients with plaque psoriasis. J Drugs Dermatol 2012; 11: 1348-1354
    PubMedGoogle Scholar
  • 10 Nakamura RC, Abreu LD, Duque-Estrada B et al. Comparison of nail laquer clobetasol efficacy at 0.05 %, 1 %, and 8 % in nail psoriasis treatment: prospective, controlled and randomized pilot study. An Bras Dermatol 2012; 87: 203-211
    CrossrefPubMedGoogle Scholar
  • 11 Raposo SC, Simoes SD, Almeida AJ et al. Advanced systems for glucocorticoids’ dermal delivery. Expert Opin Drug Deliv 2013; 10: 857-877
    CrossrefPubMedGoogle Scholar
  • 12 Patel HK, Barot BS, Parejiy BP et al. Topical delivery of clobetasol propionate loaded microemulsion based gel for effective of vitiligo: ex vivo permeation and skin irritation studies. Colloids Surf B Biointerfaces 2013; 102: 86-94
    CrossrefPubMedGoogle Scholar